MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

127.70
+4.14
+3.35%
Opening 15:21 07/28 EDT
OPEN
123.70
PREV CLOSE
123.56
HIGH
127.70
LOW
123.12
VOLUME
249.73K
TURNOVER
--
52 WEEK HIGH
128.37
52 WEEK LOW
57.66
MARKET CAP
8.31B
P/E (TTM)
-8.9638
1D
5D
1M
3M
1Y
5Y
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarte...
PR Newswire · 7h ago
News Flash: Analysts Just Made A Sizeable Upgrade To Their Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Forecasts
Biohaven Pharmaceutical Holding Company Ltd. ( NYSE:BHVN ) shareholders will have a reason to smile today, with the...
Simply Wall St. · 5d ago
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21)
Benzinga · 6d ago
Stocks That Hit 52-Week Highs On Wednesday
    During Wednesday's morning trading, 125 companies set new 52-week highs.
Benzinga · 07/21 14:51
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:52
Analyst Ratings For Biohaven Pharma Hldgs
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago
Benzinga · 07/16 18:50
Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $107
Morgan Stanley analyst Matthew Harrison maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Equal-Weight and raises the price target from $69 to $107.
Benzinga · 07/16 12:37
Morgan Stanley Adjusts Price Target on Biohaven Pharmaceutical to $107 From $69, Maintains Equal-Weight Rating
MT Newswires · 07/16 11:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHVN. Analyze the recent business situations of Biohaven Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHVN stock price target is 126.91 with a high estimate of 145.00 and a low estimate of 101.00.
EPS
Institutional Holdings
Institutions: 318
Institutional Holdings: 70.50M
% Owned: 108.33%
Shares Outstanding: 65.07M
TypeInstitutionsShares
Increased
81
6.22M
New
34
2.53M
Decreased
87
3.37M
Sold Out
47
694.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.63%
Pharmaceuticals & Medical Research
+2.06%
Key Executives
Chairman/Independent Director
Declan Doogan
Chief Executive Officer/Director
Vlad Coric
Chief Financial Officer/Treasurer
James Engelhart
Senior Vice President
Kimberly Gentile
Chief Scientific Officer
Charles Conway
Other
William Jones
Other
Elyse Stock
Other
John Tilton
Director
Kishen Mehta
Independent Director
Gregory Bailey
Independent Director
John Childs
Independent Director
Julia Gregory
Independent Director
Michael Heffernan
Independent Director
Robert Hugin
No Data
  • All
  • Financials
  • Insiders
More
About BHVN
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.

Webull offers kinds of Biohaven Pharmaceutical Holding Co Ltd stock information, including NYSE:BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.